Technology | May 02, 2014

Endologix Partners With Terso Solutions for Fully Automated Inventory Management

May 2, 2014 — Terso Solutions Inc., a provider of automated inventory management solutions for healthcare and life science, announced that Endologix Inc. has partnered with them for a fully automated, on-site consignment inventory program. Endologix chose Terso for their proven track record with both RFID (radio frequency identification device) solutions for medical device inventory management and cold chain security.

"The Endologix Nellix EndoVascular aneurysm sealing system is a next-generation treatment for abdominal aortic aneurysms (AAA). The proprietary polymer used in the Nellix procedure requires a frozen cold chain. In addition to our packaging controls we wanted to monitor polymer storage in the field to ensure supply and quality control. In Terso we found a partner with the right combination of expertise and technology." said Todd Abraham, vice president of operations for Endologix.

The polymer that is part of the Nellix system requires cold storage until it is ready to use. Endologix has commenced distributing and storing the Nellix system polymer at customer locations through Terso's RFID freezers. The RFID technology reports to Endologix the status of the polymer units in real time, making transactions, inventory usage, temperature reporting and expiration dates transparent, automatically tracked and available to both Endologix and users in a secure, Web-based interface.

"We are very excited to be working with Endologix on this innovative program," said Jason Rosemurgy, vice president of sales and marketing for Terso Solutions. "Terso Solutions was built on our ability to manage field inventory stored in remote locations worldwide, and we look forward to working with Endologix to bring this innovative new product to market."

Terso Solutions supports European operations through their facility in Mannheim, Germany, and continues to grow globally with deployments in Europe, Asia, South America and Australia.

For more information: www.endologix.com, www.tersosolutions.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init